An Office-Base Induction of Buprenorphine/Naloxone using **PEER Guideline**

Jessica Kirkwood




Faculty/Presenter Disclosures

- Faculty: Jessica Kirkwood: Clinical Lecturer UofA, Boyle McCauley Health Centre
- Relationships with financial sponsors: Grants/Research Support: N/A
 - .
 - Speakers Bureau/Honoraria: Alberta College of Family Physicians
 - Consulting Fees: N/A Patents: N/A
 - Other: N/A

Learning Objectives

At the end of this session, participants will be able to:

- Initiate a patient on Buprenorphine/Naloxone
- Provide ongoing care and support



About Buprenorphine/Naloxone

- Buprenorphine + Naloxone
 - Naloxone present to deter IV misuse
- · Administration: Sublingual tablet
 - 2 generic dosing strengths 2mg/0.5mg & 8mg/2mg
- Mechanism of Action: Partial opioid agonist, high affinity for mu receptor
- Most common adverse events: Nausea, Constipation

Subcome Training Program Handbook - https://www.subcometrainingprogr content/uploads/2017/09/SUBCXIDNE-Training-Program-Handbook-1.pdf

- Onset of action: 30-60 mins
- Peak effect: 1-4 hours
- Duration of action: Up to 2-3 days at higher doses



Precipitated Withdrawal


- Buprenorphine has a **high affinity** for the opioid receptors and will displace other opioids off the receptors
- Because it has lower intrinsic activity, the person goes into precipitated withdrawal because the receptors are only partially stimulated
- If this happens, it causes opioid withdrawal symptoms

Office-Based Induction

• In order to avoid precipitated withdrawal:

- Ensure there has been a **minimum time period** since last opioid use
 12-24 hours since last use/dose
- Evaluate the patient to see if they are in moderate-severe opioid withdrawal state
 - Clinical Opioid Withdrawal Scale (COWS) > 12
- Provide the patient with a low initial dose to minimize risk of precipitating withdrawal

COWS Clinical Opi	sychoactive Drugs. 2003 Apr-Jun;35(2):2 ate Withdrawal Scale
Reting Pulse Exer Means of the pilewise in this pile on a single mean Pulse and the pilewise in the pile of the pile Pulse rate \$1:100 2 Pulse rate \$11:120 4 Pulse rate \$10:120	GI Uppet: oree last 1/2 hour 0 No GI symptoms 1 Stomach cramps 2 Nausea or loose road 3 Vomining or disrikes 3 Multiple spicote of diarrhea or vomining
Sweizing: owe part 1/2 hour not accounted for by room tomporture or patient activity. No report of chills or flushing Subjective respect of chills or flushing Subjective respect of chills or flushing Brands of systems to hours are face Brands of systems to hours are face Subjective state of face	Trease observation of south active i hands 6 No treaser 1 Treaser can be felt, but not observed 2 Slight treasor observable 4 Gensis treasor or manufe twittching
References Observation during conservation 0 Able to sit still 1 Reports difficulty stifting still, butis able to do se 3 Frequent shifting or extranseous norvements of legiteration 5 Unable to sit uff for more than for second	Yarning Observation during assessment 0 No yarning 1 Yawang acce or roke during assessment 2 Yawang acce or roke during assessment 4 Yawang overall time/instate
Popil size 0 Popils pinned or normal size for room light 1 Popils possible barger shan normal for room light 2 Popils norderszieh dilind 5 Popils to dilated fast ado the rim of the istis is visible	Auxiety or initiability: None Parteen reports increasing initiability or auxiementes Parteen relycionsh initiabile auxieus Parteen to initiabile or auxieus that participation in the assessments is difficult
Brone or Jeinst subset of particle states and participation of the additional component attributed to optical withdrawal in coord 1 Mild different disconfort 2 Patients reports rescue diffuse aching of joints/ muscles 4 Patients to rubbing joints or muscles and is smable to site with because all disconfort	Ocosefinh skin 8 Skin is smooth 3 Ploerrection of skin can be felt er hairs standing up or arms 5 Promisant piloerrection
Runny ness or buring Not accounted for by celd symptoms or allorgies 0 Not present 1 Notal stuffiness or unumally moint eyes 2 Note running or toring 4 Note constandly running or tears streaming down checks	Total Score The total score is the sum of all 11 items Initials of person completing Assessments



Office-Based Induction: Day 2

- The daily dose is established as equivalent to the total amount that was administered on Day 1 plus additional doses for day 2.
- Doses may be subsequently increased in 4 mg increments each day as needed for ongoing treatment of withdrawal symptoms and cravings
- Dose may be increased to a maximum dose of 24 mg /day
- If side effects occur, the dose should be maintained or lowered until side effects resolve

Home Inductions

- Take-home inductions can be an effective alternative to office based inductions, for some individuals.
- Provide the patient with the Subjective Opiate Withdrawal Scale (SOWS) as a way to self-measure their level of withdrawal.
- Provide education to the patient about the need to be in withdrawal before starting the buprenorphine/naloxone.
- Ideally, the patient should be able to call a provider with questions

Caring for a Patient on Buprenorphine/Naloxone

- The goal dose is 16 24mg. You can adjust up or down by 4 mg per day.
- See the patient weekly until they are stable, then extend the prescriptions to every 4 weeks, or longer, depending on patient stability.
- If ongoing cravings, withdrawal or substance use can consider increasing beyond 24mg.

Ongoing Care for a patient on OAT

- When seeing a patient for a follow up visit ask:
 - Adequate dose?
 - Side effects?
 - Substance Use?
 - Cravings?
 - Sleep?
 - Psychosocial functioning

OAT and concurrent Benzodiazepine use

- Opioids and benzodiazepines both decrease respiratory drive.
 - should not be co-prescribed.
- Observational data suggests:^{1,2}
 - 6x increased risk of opioid overdose death when sedative-hypnotics are combined with opioids.
 - In patients on OAT for OUD, this risk is lower at $^{\sim}2x$
- If a patient is on benzodiazepines, prescribed, or illicit, that is not a reason to withhold OAT.

Med Care. 2017 Jul;55(7):661-668. Drug Alcohol Depend. 2017 May 1;174:58-64.

Special Considerations

- Pregnancy
- Acute pain or injury
- Elective Surgery
- Hospitalization
- Incarceration
- Bottom Line: Do NOT stop OAT for any of these circumstances.

Tapering

- Involuntary
- Risks > Benefits?



- Pt driven
- Maximize chance of success
- Poor prognosis if using other substances, pregnant, unstable physical or mental health, poor psychosocial fxn
- May take up to a year or longer to successfully complete cessation and few pts have a good prognosis

Questions?

